Recently, Sinovac Biotech Ltd. announced that its self-developed adsorbed tetanus vaccine has officially received approval for market launch from China’s National Medical Products Administration (NMPA). The vaccine employs advanced purification processes and aluminum adjuvant adsorption technology, offering high purity, strong safety, and excellent immunogenicity. Tetanus is an acute infectious disease caused by the exotoxin produced by Clostridium tetani, with a very high fatality rate once symptoms develop. Vaccination remains the most effective method of prevention. Sinovac’s adsorbed tetanus vaccine is indicated for active immunization in individuals aged 6 years and older and can also be used as a booster for passive immunization following injuries. The launch of this product fills a gap in the domestic market for high-quality tetanus vaccines, further enriching China’s national immunization program and providing the public with a safe and reliable preventive option. Going forward, Sinovac will continue to advance vaccine research, development, and manufacturing to support global public health initiatives.
近日，科兴控股生物技术有限公司宣布其自主研发的吸附破伤风疫苗正式获得国家药品监督管理局批准上市。该疫苗采用先进的纯化工艺和铝佐剂吸附技术，具有高纯度、高安全性和良好的免疫原性。破伤风是由破伤风梭菌产生的外毒素引起的急性感染性疾病，一旦发病，病死率极高。接种疫苗是预防破伤风最有效的方式。科兴吸附破伤风疫苗适用于6岁及以上人群的主动免疫，也可用于外伤后的被动免疫加强。该产品的上市填补了国内高品质破伤风疫苗的市场空白，进一步丰富了我国免疫规划体系，为公众提供了一种安全可靠的预防选择。未来，科兴将继续推进疫苗研发与生产，助力全球公共卫生事业的发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6925.html